Is Hims & Hers Health, Inc. overvalued or undervalued?

As of 24 October 2025, the valuation grade for Hims & Hers Health, Inc. has moved from expensive to fair. The company appears to be fairly valued based on its current metrics. Key valuation ratios include a P/E ratio of 74, an EV to EBITDA of 89.10, and a PEG ratio of 0.01, indicating potential growth relative to its price.
In comparison to peers, Hims & Hers has a P/E ratio that is higher than Addus HomeCare Corp. at 22.05 and significantly higher than Guardant Health, Inc., which has a negative P/E of -17.69. Despite the high valuation ratios, the company's strong ROCE of 50.18% and ROE of 30.96% suggest robust profitability. Over the past year, Hims & Hers has outperformed the S&P 500 with a return of 126.67% compared to the index's 16.90%, reinforcing its favorable valuation outlook.